US5516931A
(en)
|
1982-02-01 |
1996-05-14 |
Northeastern University |
Release tag compounds producing ketone signal groups
|
US4650750A
(en)
|
1982-02-01 |
1987-03-17 |
Giese Roger W |
Method of chemical analysis employing molecular release tag compounds
|
US5650270A
(en)
|
1982-02-01 |
1997-07-22 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
US4709016A
(en)
|
1982-02-01 |
1987-11-24 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
US5360811A
(en)
|
1990-03-13 |
1994-11-01 |
Hoechst-Roussel Pharmaceuticals Incorporated |
1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
|
JP3545461B2
(ja)
|
1993-09-10 |
2004-07-21 |
エーザイ株式会社 |
二環式ヘテロ環含有スルホンアミド誘導体
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
PT1235830E
(pt)
|
1999-12-10 |
2004-04-30 |
Pfizer Prod Inc |
Compostos de pirrolo¬2,3-d|pirimidina como inibidores das proteina cinases
|
DE10002509A1
(de)
|
2000-01-21 |
2001-07-26 |
Gruenenthal Gmbh |
Substituierte Glutarimide
|
EP1259514B9
(en)
|
2000-02-28 |
2005-11-09 |
Sugen, Inc. |
3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
AU2001295041A1
(en)
|
2000-09-08 |
2002-03-22 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
US7208157B2
(en)
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
CN1310907C
(zh)
|
2001-04-27 |
2007-04-18 |
全药工业株式会社 |
杂环化合物和以其为有效成分的抗肿瘤药
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
IL166718A0
(en)
|
2002-08-14 |
2006-01-15 |
Atugen Ag |
Further use of protein kinase n beta
|
EA012240B1
(ru)
|
2003-04-03 |
2009-08-28 |
Семафор Фармасьютикалз, Инк. |
Пролекарства ингибиторов киназы pi-3
|
WO2004106328A1
(en)
|
2003-05-30 |
2004-12-09 |
Gemin X Biotechnologies Inc. |
Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
|
CA2531069A1
(en)
|
2003-07-03 |
2005-01-27 |
The Trustees Of The University Of Pennsylvania |
Inhibition of syk kinase expression
|
JP4398263B2
(ja)
|
2004-01-13 |
2010-01-13 |
富士通株式会社 |
経路設計方法
|
EP2612862B1
(en)
|
2004-05-13 |
2016-09-14 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
ATE451381T1
(de)
|
2005-01-19 |
2009-12-15 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
CA2606147C
(en)
|
2005-05-12 |
2011-07-05 |
Abbott Laboratories |
Apoptosis promoters
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
KR101607288B1
(ko)
|
2005-07-01 |
2016-04-05 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
ES2513165T3
(es)
|
2005-10-07 |
2014-10-24 |
Exelixis, Inc. |
Derivados de N-(3-amino-quinoxalin-2-il)-sulfonamida y su uso como inhibidores de la fosfatidilinositol-3-quinasa
|
NZ567851A
(en)
|
2005-11-01 |
2011-09-30 |
Targegen Inc |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
BRPI0619817B8
(pt)
|
2005-12-13 |
2021-05-25 |
Incyte Corp |
composto 3-ciclopentil-3-[4-(7h-pirrol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrila e sua composição
|
KR101397915B1
(ko)
|
2005-12-23 |
2014-05-26 |
와이어쓰 엘엘씨 |
개질된 리신 모방 화합물
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
DK2024372T3
(da)
|
2006-04-26 |
2010-09-20 |
Hoffmann La Roche |
Thieno[3,2-d]pyrimidin-derivat, der er egnet som P13K inhibitor
|
PL2526771T3
(pl)
|
2006-09-22 |
2017-06-30 |
Pharmacyclics Llc |
Inhibitory kinazy tyrozynowej Brutona
|
US20100279316A1
(en)
|
2007-01-19 |
2010-11-04 |
Leonid Gorelik |
Antibodies to Phosphorylated IRAK4
|
US8486941B2
(en)
|
2007-03-12 |
2013-07-16 |
Ym Biosciences Australia Pty Ltd |
Phenyl amino pyrimidine compounds and uses thereof
|
US8394794B2
(en)
|
2007-03-23 |
2013-03-12 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
AU2008275589B2
(en)
|
2007-07-12 |
2013-11-21 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
CA2703519C
(en)
|
2007-11-09 |
2017-04-18 |
The Salk Institute For Biological Studies |
Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
|
CA2707308C
(en)
|
2007-11-30 |
2016-08-02 |
Newlink Genetics Corporation |
Ido inhibitors
|
NZ587928A
(en)
|
2008-03-11 |
2012-08-31 |
Incyte Corp |
Azetidine and cyclobutane derivatives as jak inhibitors
|
EP2291187B1
(en)
|
2008-04-24 |
2018-08-15 |
Newlink Genetics Corporation |
Ido inhibitors
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
EP3929216A1
(en)
|
2008-12-09 |
2021-12-29 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
US8921037B2
(en)
|
2008-12-16 |
2014-12-30 |
Bo Han |
PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
|
BR112012004823B1
(pt)
|
2009-09-03 |
2021-11-30 |
Merck Sharp & Dohme Corp |
Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
|
JP2012254939A
(ja)
|
2009-10-07 |
2012-12-27 |
Astellas Pharma Inc |
オキサゾール化合物
|
WO2011056652A1
(en)
|
2009-10-28 |
2011-05-12 |
Newlink Genetics |
Imidazole derivatives as ido inhibitors
|
RS54596B1
(en)
|
2009-12-10 |
2016-08-31 |
F. Hoffmann-La Roche Ag |
Antibodies Binding to Extracellular Domain 4 of Human CSF1R and Their Use
|
RU2567753C2
(ru)
*
|
2010-02-11 |
2015-11-10 |
Селджин Корпорейшн |
Производные арилметокси изоиндолина и композиции, включающие их, и способы их применения
|
BR112012022210B1
(pt)
|
2010-03-04 |
2021-08-17 |
Macrogenics, Inc |
Anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
|
KR101647871B1
(ko)
|
2010-03-05 |
2016-08-11 |
에프. 호프만-라 로슈 아게 |
인간 csf-1r에 대한 항체 및 이의 용도
|
MX2012010014A
(es)
|
2010-03-05 |
2012-09-21 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano y sus usos.
|
US8114621B2
(en)
|
2010-03-12 |
2012-02-14 |
Saladax Biomedical Inc. |
Lenalidomide and thalidomide immunoassays
|
TR201900368T4
(tr)
|
2010-05-04 |
2019-02-21 |
Five Prime Therapeutics Inc |
Csf1r'ye bağlanan antikorlar.
|
CN103153335A
(zh)
|
2010-06-30 |
2013-06-12 |
布兰代斯大学 |
小分子靶定的蛋白质降解
|
RU2604062C2
(ru)
|
2010-07-13 |
2016-12-10 |
Ф.Хоффманн-Ля Рош Аг |
ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4
|
MY177065A
(en)
|
2010-09-09 |
2020-09-03 |
Pfizer |
4-1bb binding molecules
|
CN108864151A
(zh)
|
2010-11-19 |
2018-11-23 |
利亘制药公司 |
杂环胺及其用途
|
WO2012078559A2
(en)
|
2010-12-07 |
2012-06-14 |
Yale University |
Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
|
DK3214091T3
(en)
|
2010-12-09 |
2019-01-07 |
Univ Pennsylvania |
USE OF CHEMICAL ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CANCER
|
SG191205A1
(en)
|
2010-12-20 |
2013-07-31 |
Merck Serono Sa |
Indazolyl triazole derivatives as irak inhibitors
|
WO2012097013A1
(en)
|
2011-01-10 |
2012-07-19 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
EP2688872A4
(en)
|
2011-03-22 |
2014-08-27 |
Merck Sharp & Dohme |
AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES
|
NO2694640T3
(es)
|
2011-04-15 |
2018-03-17 |
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン,エルエルシー |
B7−h1およびpd−1に結合する抗体およびその他の分子
|
WO2013042137A1
(en)
|
2011-09-19 |
2013-03-28 |
Aurigene Discovery Technologies Limited |
Bicyclic heterocycles as irak4 inhibitors
|
US9221809B2
(en)
|
2011-10-31 |
2015-12-29 |
Merck Sharp & Dohme Corp. |
Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
|
PT2785375T
(pt)
|
2011-11-28 |
2020-10-29 |
Merck Patent Gmbh |
Anticorpos anti-pd-l1 e usos destes
|
MX356337B
(es)
|
2011-12-15 |
2018-05-23 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano y sus usos.
|
TW201728592A
(zh)
|
2012-01-10 |
2017-08-16 |
林伯士艾瑞斯公司 |
Irak抑制劑及其用途
|
WO2013106646A2
(en)
|
2012-01-12 |
2013-07-18 |
Yale University |
Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
|
CA2861066C
(en)
|
2012-01-12 |
2024-01-02 |
Yale University |
Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
|
ES2630705T3
(es)
|
2012-01-13 |
2017-08-23 |
Bristol-Myers Squibb Company |
Compuestos de piridilo sustituidos con triazolilo útiles como inhibidores de cinasas
|
US9242975B2
(en)
|
2012-01-13 |
2016-01-26 |
Bristol-Myers Squibb Company |
Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
|
JP6096219B2
(ja)
|
2012-01-13 |
2017-03-15 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
キナーゼ阻害剤として有用なトリアゾリルまたはトリアジアゾリル置換されたピリジル化合物
|
KR20140127855A
(ko)
|
2012-02-06 |
2014-11-04 |
제넨테크, 인크. |
Csf1r 억제제를 사용하는 조성물 및 방법
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
BR112014028013A2
(pt)
|
2012-05-11 |
2018-02-27 |
Five Prime Therapeutics Inc |
métodos para tratar uma condição associada com artrite reumatoide, artrite reumatoide, lesões de pele, nefrite lúpica, lúpus, uma condição inflamatória, distúrbio de cd16+, método para reduzir o número de monócitos cd16+, métodos para desacelerar a progressão de uma condição renal,de formação de panos e de perda óssea
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
AU2013289615B2
(en)
|
2012-07-10 |
2017-06-08 |
Ares Trading S.A. |
Pyrimidine pyrazolyl derivatives
|
WO2014011911A2
(en)
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
BR112015000561A2
(pt)
|
2012-07-11 |
2017-06-27 |
Nimbus Iris Inc |
inibidores de irak e usos dos mesmos
|
WO2014011902A1
(en)
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
SG11201501413YA
(en)
|
2012-08-31 |
2015-03-30 |
Five Prime Therapeutics Inc |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
WO2014044622A1
(en)
|
2012-09-19 |
2014-03-27 |
F. Hoffmann-La Roche Ag |
2-oxo-2,3,4,5-tetrahydro-1 h-benzo[b]diazepines and their use in the treatment of cancer
|
EP2903613B1
(en)
|
2012-10-08 |
2017-11-22 |
Merck Sharp & Dohme Corp. |
Pyrazole derivatives useful as inhibitors of irak4 activity
|
EP2903617B1
(en)
|
2012-10-08 |
2019-01-30 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
WO2014063061A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
WO2014074675A1
(en)
|
2012-11-08 |
2014-05-15 |
Bristol-Myers Squibb Company |
Heteroaryl substituted pyridyl compounds useful as kinase modulators
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
AU2014214254B2
(en)
|
2013-02-07 |
2018-03-29 |
Merck Patent Gmbh |
Macrocyclic Pyridazinone derivatives
|
SI2953944T1
(sl)
|
2013-02-07 |
2017-08-31 |
Merck Patent Gmbh |
Piridazinonamidni derivati
|
EP2970334B1
(en)
|
2013-03-15 |
2018-05-23 |
Biogen MA Inc. |
Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases
|
MX2016003843A
(es)
|
2013-09-27 |
2017-02-15 |
Nimbus Iris Inc |
Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
|
CA2925944C
(en)
|
2013-10-04 |
2023-01-10 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015068856A1
(en)
|
2013-11-08 |
2015-05-14 |
Takeda Pharmaceutical Company Limited |
Pyrazole for the treatment autoimmune disorders
|
BR112016008468A2
(pt)
|
2013-11-18 |
2017-10-03 |
Hoffmann La Roche |
Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
|
BR112016012146B1
(pt)
|
2013-11-27 |
2022-11-01 |
Signalchem Lifesciences Corporation |
Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
|
TWI667233B
(zh)
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
UY35935A
(es)
|
2014-01-03 |
2015-06-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
|
MX2016009011A
(es)
|
2014-01-10 |
2017-01-23 |
Aurigene Discovery Tech Ltd |
Compuestos de indazol como inhibidores de cinasa-4 asociada al receptor de interleucina-1 (irak4).
|
IL294895B2
(en)
|
2014-01-13 |
2023-10-01 |
Aurigene Oncology Ltd |
History of bicyclic heterocyclyls as IRAK4 inhibitors
|
EP3119760A1
(en)
|
2014-03-17 |
2017-01-25 |
F. Hoffmann-La Roche AG |
Piperidine-dione derivatives
|
MY185837A
(en)
|
2014-03-19 |
2021-06-12 |
Boehringer Ingelheim Int |
Heteroaryl syk inhibitors
|
ES2910128T3
(es)
|
2014-04-04 |
2022-05-11 |
Pfizer |
Compuestos de heteroarilo o arilo fusionados con biciclo y su uso como inhibidores de IRAK4
|
KR20210132233A
(ko)
|
2014-04-14 |
2021-11-03 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
EP3134091A4
(en)
|
2014-04-22 |
2017-08-30 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
JP2017518348A
(ja)
|
2014-06-20 |
2017-07-06 |
オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited |
Irak4阻害剤としての置換インダゾール化合物
|
EP3160486B1
(en)
|
2014-06-27 |
2020-11-18 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
US10246456B2
(en)
|
2014-07-18 |
2019-04-02 |
Biogen Ma Inc. |
IRAK4 inhibiting agents
|
US20160022642A1
(en)
|
2014-07-25 |
2016-01-28 |
Yale University |
Compounds Useful for Promoting Protein Degradation and Methods Using Same
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
WO2016053771A1
(en)
|
2014-09-30 |
2016-04-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
US9932350B2
(en)
|
2014-09-30 |
2018-04-03 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
US9943516B2
(en)
|
2014-09-30 |
2018-04-17 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
WO2016053769A1
(en)
|
2014-09-30 |
2016-04-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
AU2015349899B9
(en)
|
2014-11-20 |
2020-06-25 |
Merck Patent Gmbh |
Heteroaryl compounds as IRAK inhibitors and uses thereof
|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
US20170327469A1
(en)
|
2015-01-20 |
2017-11-16 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
EP3268367B8
(en)
|
2015-03-12 |
2022-11-16 |
Merck Sharp & Dohme LLC |
Carboxamide inhibitors of irak4 activity
|
WO2016144847A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrrolopyridazine inhibitors of irak4 activity
|
WO2016144849A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of irak4 activity
|
WO2016144846A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of irak4 activity
|
EP3268006B1
(en)
|
2015-03-12 |
2020-01-08 |
Merck Sharp & Dohme Corp. |
Pyrrolotriazine inhibitors of irak4 activity
|
AU2016232705C1
(en)
|
2015-03-18 |
2021-06-17 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
GB201504763D0
(en)
|
2015-03-20 |
2015-05-06 |
Mironid Ltd |
Compounds and uses
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
LT3286181T
(lt)
|
2015-04-22 |
2021-04-26 |
Rigel Pharmaceuticals, Inc. |
Pirazolo junginiai ir junginių gamybos bei naudojimo būdas
|
TW201701879A
(zh)
|
2015-04-30 |
2017-01-16 |
拜耳製藥公司 |
Irak4抑制劑組合
|
BR112017025975B1
(pt)
|
2015-06-04 |
2023-12-12 |
Arvinas Operations, Inc |
Composto, composição, método in vitro para induzir degradação de uma proteína alvo em uma célula, e, uso de uma composição
|
EP3302482A4
(en)
|
2015-06-05 |
2018-12-19 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
CA2986441A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
TW201718571A
(zh)
|
2015-06-24 |
2017-06-01 |
必治妥美雅史谷比公司 |
經雜芳基取代之胺基吡啶化合物
|
CN105085620B
(zh)
|
2015-06-25 |
2018-05-08 |
中山大学附属第一医院 |
一种靶向泛素化降解Smad3的化合物
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
WO2017004133A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
AU2016291578C1
(en)
|
2015-07-10 |
2021-07-15 |
Arvinas Operations, Inc. |
MDM2-based modulators of proteolysis and associated methods of use
|
US20170037004A1
(en)
|
2015-07-13 |
2017-02-09 |
Arvinas, Inc. |
Alanine-based modulators of proteolysis and associated methods of use
|
CN107849013B
(zh)
|
2015-07-14 |
2022-03-29 |
特殊治疗有限公司 |
作为dub抑制剂用于治疗癌症的氰基吡咯烷类
|
BR112018000624A2
(pt)
|
2015-07-15 |
2018-09-18 |
Aurigene Discovery Technologies Limited |
compostos de indazol e azaindazol como inibidores de irak-4
|
EA201890308A1
(ru)
|
2015-07-15 |
2018-08-31 |
Ориджин Дискавери Текнолоджиз Лимитед |
Замещенные азасоединения как ингибиторы irak-4
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
HUE053705T2
(hu)
|
2015-08-27 |
2021-07-28 |
Pfizer |
Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként
|
MX2018002986A
(es)
|
2015-09-18 |
2018-05-02 |
Merck Patent Gmbh |
Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
|
BR112018003812B1
(pt)
|
2015-09-18 |
2024-04-30 |
Merck Patent Gmbh |
Compostos de heteroarila como inibidores de irak, seu uso, composição farmacêutica, e kit
|
PE20181068A1
(es)
|
2015-10-02 |
2018-07-04 |
Dana Farber Cancer Inst Inc |
Terapia de combinacion de inhibidores de bromodominios y bloqueo de puntos de control
|
WO2017059280A1
(en)
|
2015-10-02 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Novel pan-tam inhibitors and mer/axl dual inhibitors
|
WO2017079267A1
(en)
|
2015-11-02 |
2017-05-11 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
CN108473498B
(zh)
|
2015-12-22 |
2021-11-02 |
豪夫迈·罗氏有限公司 |
作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
|
WO2017117474A1
(en)
|
2015-12-30 |
2017-07-06 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional compounds for her3 degradation and methods of use
|
US20200216454A1
(en)
|
2015-12-30 |
2020-07-09 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molecules for her3 degradation and methods of use
|
WO2017127430A1
(en)
|
2016-01-20 |
2017-07-27 |
Biogen Ma Inc. |
Irak4 inhibiting agents
|
MX2022008085A
(es)
|
2016-03-16 |
2022-07-11 |
H Lee Moffitt Cancer Ct & Res |
Moleculas peque?as contra cereblon para mejorar la funcion efectora de los linfocitos t.
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
SG11201808728QA
(en)
|
2016-04-06 |
2018-11-29 |
Univ Michigan Regents |
Mdm2 protein degraders
|
JP7001614B2
(ja)
|
2016-04-06 |
2022-02-03 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
リガンド依存性の標的タンパク質分解のための単官能性中間体
|
WO2017197055A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
EP3455219A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
EP3454862A4
(en)
|
2016-05-10 |
2020-02-12 |
C4 Therapeutics, Inc. |
SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
WO2017197056A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
WO2017201069A1
(en)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Oxoindoline derivatives as protein function modulators
|
ES2858151T3
(es)
|
2016-05-20 |
2021-09-29 |
Hoffmann La Roche |
Conjugados de PROTAC-anticuerpo y procedimientos de uso
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017207385A1
(de)
|
2016-05-31 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Substituierte 3-methylindazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
|
GB201610147D0
(en)
|
2016-06-10 |
2016-07-27 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
EP3475263B1
(en)
|
2016-06-27 |
2022-12-28 |
Rigel Pharmaceuticals, Inc. |
2,4-diamino-pyrimidine compounds and their use as irak4 inhibitors
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
JP2019196309A
(ja)
|
2016-09-15 |
2019-11-14 |
武田薬品工業株式会社 |
複素環化合物
|
US10925868B2
(en)
|
2016-11-10 |
2021-02-23 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
|
WO2018098367A1
(en)
|
2016-11-22 |
2018-05-31 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
|
KR20190101406A
(ko)
|
2016-12-23 |
2019-08-30 |
아비나스 오퍼레이션스, 인코포레이티드 |
Egfr 단백질분해 표적화 키메라 분자 및 관련 사용 방법
|
CN110612294B
(zh)
|
2017-01-31 |
2024-01-16 |
阿尔维纳斯运营股份有限公司 |
人小脑蛋白配体和包含其的双官能化合物
|
JOP20180011A1
(ar)
|
2017-02-16 |
2019-01-30 |
Gilead Sciences Inc |
مشتقات بيرولو [1، 2-b]بيريدازين
|
PE20191817A1
(es)
|
2017-05-11 |
2019-12-27 |
Bristol Myers Squibb Co |
Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
WO2019043214A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
glutarimide
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
IL295603B2
(en)
|
2017-09-22 |
2024-03-01 |
Kymera Therapeutics Inc |
Protein compounds and their uses
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
WO2019084026A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
|
WO2019099868A2
(en)
|
2017-11-16 |
2019-05-23 |
C4 Therapeutics, Inc. |
Degraders and degrons for targeted protein degradation
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
MX2020006812A
(es)
|
2017-12-26 |
2020-11-06 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
US11542251B2
(en)
|
2018-02-14 |
2023-01-03 |
Dana-Farber Cancer Institute, Inc. |
IRAK degraders and uses thereof
|
EP3755325A4
(en)
|
2018-02-23 |
2022-03-02 |
Dana-Farber Cancer Institute, Inc. |
SMALL MOLECULES FOR INDUCING SELECTIVE PROTEIN DEGRADATION AND THEIR USES
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
US20220356185A1
(en)
|
2018-07-06 |
2022-11-10 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
AU2019307631A1
(en)
|
2018-07-20 |
2020-12-17 |
Dana-Farber Cancer Institute, Inc. |
Degraders that target proteins via KEAP1
|
EP3886904A4
(en)
|
2018-11-30 |
2022-07-13 |
Kymera Therapeutics, Inc. |
IRAQ-TYPE KINASE DEGRADING AGENTS AND THEIR USES
|
US20230149549A1
(en)
|
2019-06-10 |
2023-05-18 |
Kymera Therapeutics, Inc |
Smarca degraders and uses thereof
|
WO2020251974A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca inhibitors and uses thereof
|
WO2020251971A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
WO2020251969A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
WO2020264499A1
(en)
|
2019-06-28 |
2020-12-30 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
WO2020264490A1
(en)
|
2019-06-28 |
2020-12-30 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
US20230093080A1
(en)
|
2019-07-15 |
2023-03-23 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
US20220281831A1
(en)
|
2019-07-15 |
2022-09-08 |
Kymera Therapeutics, Inc. |
Fused-glutarimide crbn ligands and uses thereof
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
WO2021011871A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
CN114401960A
(zh)
|
2019-09-16 |
2022-04-26 |
诺华股份有限公司 |
胶降解剂及其使用方法
|
US11779578B2
(en)
|
2019-12-17 |
2023-10-10 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
US20230219945A1
(en)
|
2019-12-17 |
2023-07-13 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|